1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

UCB Buoyed By More Positive Bimekizumab Data

 
• By Kevin Grogan

The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.

Train
Still time for UCB to get on the IL-17 train • Source: Shutterstock

UCB Group may be late to the party when it comes to the interleukin-17 space for immune disorders but with more promising data on bimekizumab for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), the Belgian firm remains confident of getting a foothold in the market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas